A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

BACKGROUND: Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily targeting somatostatin receptor (sstr) subtypes 2 and 5, in neuroendocrine tumors (NET). Pasireotide, a second-generation SSA, targets multiple sstr subtypes. We compared t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., Yao, J.C.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
GASTROINTESTINAL TUMOR
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360140/
https://ncbi.nlm.nih.gov/pubmed/28327907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx078
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki